SCHEMBL3569674

SCHEMBL3569674

CCCc1ccc(-c2ccccc2)c([O])c1CCC

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
GAA P10253 1/20 0.37
HPGD P15428 1/20 0.37
MAPT P10636 1/20 0.35
PPARA Q07869 1/20 0.35
LTB4R Q15722 1/20 0.34
LTB4R2 Q9NPC1 1/20 0.34
SOAT1 P35610 2/20 0.34
PPARG P37231 2/20 0.34
ELANE P08246 1/20 0.34
CTSG P08311 1/20 0.34
CTSL P07711 1/20 0.34
CTSS P25774 1/20 0.34
CTSK P43235 1/20 0.34
ADORA3 P0DMS8 1/20 0.33
ADORA2A P29274 1/20 0.33
ADORA1 P30542 1/20 0.33
CYBB P04839 1/20 0.33
NOX4 Q9NPH5 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4506021 0.84 KDM4E (0.40) KDM4EALDH1A1GAAHPGDMAPT
SCHEMBL3561166 0.80 DPP4 (0.35) MAPTADORA3PDCD1CD274DPP4
SCHEMBL3563200 0.79 PDCD1 (0.46) MAPTPPARASOAT1ELANECTSG
SCHEMBL7305833 0.77 PRKCI (0.37) KDM4EALDH1A1GAAHPGDELANE
SCHEMBL6139588 0.77 PDCD1 (0.47) KDM4EALDH1A1GAAHPGDMAPT
Bicarbonate SCHEMBL28364704 0.75 FOLH1 (0.50) PPARALTB4RLTB4R2SOAT1PPARG
SCHEMBL11057507 0.74 ALDH1A1 (0.41) KDM4EALDH1A1GAAHPGDMAPT
SCHEMBL4629945 0.74 MAPT (0.39) MAPTPPARAADORA3ADORA2AADORA1
SCHEMBL27727020 0.73 KDM4E (0.39) KDM4EALDH1A1GAAHPGDMAPT
SCHEMBL9342239 0.73 PDCD1 (0.47) MAPTPPARACTSKADORA3ADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1653960-A4 MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONIST AMGEN INC (US) 2008-11-26 EP claimed
EP-1653960-A2 MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONIST AMGEN INC. (US) 2006-05-10 EP claimed
US-20050215526-A1 Melanin concentrating hormone receptor antagonist AMGEN, INC. 2005-09-29 US claimed
WO-2005019167-A2 MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONIST AMGEN, INC. (US) 2005-03-03 WO claimed
US-7659276-B2 Melanin concentrating hormone receptor antagonist AMGEN, INC. (US) 2010-02-09 US disclosed
US-20090143405-A1 MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONIST AMGEN, INC. (US) 2009-06-04 US disclosed
US-7514438-B2 Melanin concentrating hormone receptor antagonist AMGEN, INC. (US) 2009-04-07 US disclosed
EP-1653960-A4 MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONIST AMGEN INC (US) 2008-11-26 EP disclosed
EP-1653960-A2 MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONIST AMGEN INC. (US) 2006-05-10 EP disclosed
US-20050215526-A1 Melanin concentrating hormone receptor antagonist AMGEN, INC. 2005-09-29 US disclosed
WO-2005019167-A2 MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONIST AMGEN, INC. (US) 2005-03-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143405-A1 MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONIST MCHR1, MC1R, NPY1R KDM4E 3530/4885ALDH1A1 2113/4885GAA 1071/4885
US-20050215526-A1 Melanin concentrating hormone receptor antagonist MCHR1, MC1R, NPY1R KDM4E 3530/4885ALDH1A1 2113/4885GAA 1071/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.